Founder、Chairman
Founder、Chairman
PhD
Distinguished Experts, Chair Professor
Professor LIU earned his Ph.D. in Cell Biology from University of Maryland in College Park, and then did his postdoctoral trainings in Johns Hopkins University School of Medicine, and in California Institute of Technology Division of Biology, USA. He was a tenured full professor in the Institute of Biosesciences and Technology, Texas A&M University, and the graduate faculty member in the University of Texas Houston Medical School and UT MD Anderson Cancer Center. After returned to China, Prof. LIU has served as the Dean of Life Sciences for 8 years and has been the Director of Institute of Biomedical Sciences, East China Normal University in Shanghai.
Prof. LIU's research interests focus on cell signaling, cell therapy, gene editing and gene therapy in different diseases. He has published more than 400 research papers in top journals, such as Nature, Science, Nature Biotechnology, Nature Medicine, etc . He has won the first prize of National Science and Technology Progress Award, the first prize of Shanghai Science and Technology Progress Award, and the Shanghai Magnolia Memorial Award.
Founder，Vice Chairman
Founder ，Vice Chairman
EMBA of China Europe International Business School and Tsinghua University
Shanghai Minhang Leading Talent
Serial Entrepreneur
XI is a serial entrepreneur with a strong sense of corporate mission and entrepreneurial spirit, emphasizing strategic height and execution. According to his rich experience in operation, management and investment, involving various fields such as biomedicine, great health, and real estate, he currently serves as a core member of the board of directors and the company's decision-making and management committee to drive the development of BRL Medicine.
Senior Partner、Chief Executive Officer（CEO）
Senior Partner、Chief Executive Officer（CEO）
PhD
Dr. Biao Zheng graduated from the medical department of the Medical College of Zhejiang University with a bachelor's degree in clinical medicine. He received his MS and PhD in Immunology from Fudan University School of Medicine and King's College, University of London, respectively. Dr. Zheng has taught at the University of Maryland School of Medicine and Duke University Medical Center. Subsequently, he served as a tenured professor in the Department of Pathology and Immunology at Baylor College of Medicine. Dr. Zheng has published a number of papers in the world top journals such as Nature and Science.
Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. In 2015, he joined Johnson & Johnson as global vice president in Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific. Before joining BRL Medicine Inc., he joined IASO Biotherapeutics as the chief scientific officer 2020.
Dr. Zheng has more than 30 years of experience in the pharmaceutical industry, especially in the field of immunotherapy (macromolecular antibody, cell therapy, etc.). He has deep insights and experience in drug development, international medical environment, market access and commercialization.
Co-founder, Vice President
Co-founder, Vice President
PhD , Professor at East China Normal University
Dr. Li is a pioneer in the field of innovative genome editing tool development and CRISPR-based gene therapy. He has published more than 100 research articles in high impact journals, including Nature Biotechnology, Nature Genetics and Nature Cell Biology, and developed several novel editing tools, such as hyCBE and A&C-BEmax.
Co-founder, Vice President
Co-founder, Vice President
PhD , Post-Doctoral Harvard University, Researcher of East China Normal University
Researcher Yuxuan Wu has published more than 10 relevant research papers in recent years in several journals including internationally renowned academic journals Nature Medicine, Cell Stem Cell, Cell Research, Nature Genetics and Nature Biotechnology. A number of works have been widely recognized and highly evalsuated by domestic and international peers, majoring in combining gene editing technology (CRISPR) with hematopoietic stem cell transplantation for the treatment of thalassemia and other blood disorders. He was selected as a "Zijiang Outstanding Young Scholar" of East China Normal University in 2018.
Co-founder, Vice President
Co-founder, Vice President
PhD , Professor of East China Normal University
Prof. Bing Du is mainly engaged in regulation of tumor immune microenvironment and cancer immune therapy. In recent years, he has published more than 40 SCI papers in the high impact journals such as Science Advances, Cancer Research, Cancer Immunology Research, Cellular & Molecular Immunology and Mucosal Immunology. Meanwhile, he has been authorized more than 10 national invention patents in the past few years.
Co-Partner, Vice President, VP of Medical Affairs
Co-Partner, Vice President, VP of Medical Affairs
PhD
Chris Wang graduated from Anhui Medical University in 1999, majoring in clinical medicine. He received his master's and doctor's degrees in oncology pharmacology from Wannan Medical College and Shanghai Institute of Pharmaceutical Industry. Chris Wang has 18 years of working experience in hospitals and pharmaceutical companies. He has held clinical development, medical affairs and pre-clinical research positions in Sanofi, Novartis, Junshi, JW, Genor, etc. Led/participated in clinical research and development work in solid tumors, hematologic malignancies, autoimmune diseases, neurological disease and rare diseases, etc. Participated in the formulation and interpretation of CDE guidelines for CGT industries several times, and gained extensive experience in early phase and pivotal studies in CGT, biological products, antitumor vaccines. Prior to joining BRL Medicine Inc., Chris Wang served as senior director and project lead of clinical development at JW Therapeutics.
Co-Partner, Vice President, R&D
Co-Partner, Vice President, R&D
PhD , AssociateProfessor
Jiqin Zhang is focused on the research of gene editing and tumor immune cell therapy. In recent years, he has published more than 20 SCI papers in international journals such as Nature, Nature Communications, Cell Research, Molecular Cancer and Hypertension. As a leader, he has taken charge of two projects of National Natural Science Foundation of China and one project of Shanghai Natural Science Foundation. He also participated in several national and provincial scientific research projects. He has developed an international first non-viral genome specific targeted CAR T cell technology, established the Quikin CART® platform with BRL proprietary intellectual property, providing new strategies to break through the limitations of current CAR T cell therapy.
Co-Partner, Vice President of Production and CMC
Co-Partner, Vice President of Production and CMC
PhD
During his graduate studies, Dr. Binghe Tan focused on the role and mechanism of G protein-coupled receptors and their signaling in the regulation of tumor immunity, exploring the regulation of G protein-coupled receptor-mediated immune cell function and revealing the important roles and mechanisms of macrophages, T cells and other immune cells in the tumor microenvironment. In addition, he has been working on immunotherapy based on the regulation of tumor immune microenvironment. His postdoctoral work focuses on the genericization and functional enhancement of chimeric antigen receptor T cells (CAR-T) using gene editing technology, as well as the development and optimization of engineered T cell preparation processes, with the aim of achieving safety, efficacy and stability goals of universal CART (UCART) in clinical translational applications. He has been published as first author and co-author in Cancer Research, Journal of Immunology, Journal of Biological Chemistry, Science China Life Sciences, Cellular & Molecular Immunology, etc. He has applied for one international invention patent and four Chinese invention patents, one of which has been transferred. He presided over one National Natural Science Foundation of China (NSFC) youth project and participated in several NSFC surface projects as a key technicaldirector.
Co-Partner, Chief Human Resource Officer
Co-Partner, Chief Human Resource Officer
MBA of Wuhan University
CPM® International Certified Property Manager, Certified Instructor of Leadership and Human Resource ManagementNan Xu has worked in human resource management in Dowell Group, Shimao Group, China Resources Group and China Vanke. She has served as HR administrative director of commercial section, assistant HR director of the group, head of HR administration of regional companies, and senior manager of performance management of the group. Has nearly twenty years of experience in organizational development, corporate culture and talent management. Served as a volunteer for the Dima Charity Foundation during the novel coronavirus outbreak, coordinating the procurement of overseas medical supplies. Now she is responsible for the management of human resources, administration and public affairs of the company.
Co-Partner, Vice President, R&D
Co-Partner, Vice President, R&D
Ph.D. in Immunology, Post-Doctoral, East China Normal University
Dr. Na Zhang has long been engaged in the field of cancer immune therapy, especially in cell therapy.
She has developed innovative solid tumor CAR T cell products（Prostate Cancer, Gastric Cancer & Ovarian Cancer et.al.）.
She has hosted National Natural Science Foundation of China & Postdoctoral Foundation, and published several SCI papers in well-known international journals.
Meanwhile, she has been authorized more than 10 national invention patents.
Co-Partner, Director of Marketing & Intellectual Property
Co-Partner, Director of Marketing & Intellectual Property
Anling Huang graduated from East China Normal University with a Master's degree in Biochemistry and Molecular Biology. She won the nomination award of top 30 cutting-edge women in China's intellectual property circle in 2021 and published 3 papers in International Academic Journals. Anling is responsible for company's Intellectual Property & Marketing affairs, and has led the company to obtain honorary titles such as "Shanghai patent pilot enterprise" and "intellectual property management system certification certificate".
